By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GenMark Diagnostics, formerly known as Osmetech, today said that its US initial public offering has been priced at $6 per share, down from an earlier range of $8 to $10.

The company, which concurrent with the IPO changed its name to GenMark Diagnostics, is offering 4.6 million shares, and said that it expects trading to begin today on the Nasdaq Global Market under the symbol "GNMK."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.